Market research
CLBS Caladrius Biosciences Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 0.91
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 26M
- P/E ratio
- Not available
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 0.91
About
About Caladrius Biosciences Inc
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Research context
Caladrius Biosciences Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CLBS discussion.
5 years, 6 months ago
Caladrius Biosciences, Inc is currently in a long term downtrend where the price is trading 11.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Caladrius Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 9.6% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 32.1% to $-6M since the same quarter in the previous year.
Based on the above factors, Caladrius Biosciences, Inc gets an overall score of 1/5.